Effects of somatostatin analogues on human sphincter of Oddi pressure.
BACKGROUND
Somatostatin, a neuropeptide and hormone, exists in the biliary tract of several species. The effects of somatostatin and its analogues on the sphincter of Oddi motility have been controversial. The aim of this study was to observe the action of stilamin and sandostatin on the sphincter of Oddi via choledochofiberscope manometry.


METHODS
Twenty patients who had had "T" duct after cholecystectomy and choledochotomy were divided into 2 groups randomly: stilamin and sandostatin. They were subjected to manometry via a choledochofiberscope through the "T" duct tract. The following data recorded included duodenal pressure (DP), sphincter of Oddi basal pressure (SOBP), sphincter of Oddi contractive amplitude (SOCA), frequency of the sphincter of Oddi (SOF), duration of the sphincter of Oddi, and the common bile duct pressure (CBDP).


RESULTS
After intravenous administration of stilamin at a dose of 250 microg/h, the mean SOCA increased from 89.18(26.50) to 128.57(54.21) mmHg (P<0.05). After the administration of stilamin at a dose of 500 microg/h the mean SOCA declined to 92.18(42.81) mmHg (P<0.05), and mean SOBP declined from 17.63(13.36) to 8.16(4.01) mmHg (P<0.05). Although SOF had declined from 9.25(2.45) to 7.46(1.52) n/min, it was not significantly influenced. After intravenous administration of sandostatin at a dose of 100 microg, the mean CBDP increased obviously.


CONCLUSIONS
Intravenous administration of stilamin at a dose of 250 microg/h stimulates the motility of the sphincter of Oddi whereas the injection of stilamin at a dose of 500 microg/h inhibits its motility. Intravenous injection of sandostatin of 100 mug has no effect on the sphincter of Oddi.
Wu
Shuo-Dong
SD
Department of General Surgery, Second Affiliated Hospital, China Medical University, Shenyang 110004, China. wushuodong@hotmail.com
Zhang
Zhen-Hai
ZH
Kong
Jing
J
Li
Yan-Jun
YJ
Jin
Jun-Zhe
JZ
Wang
Wei
W
Li
Dong-Yan
DY
Wang
Min-Fei
MF
D000328:Adult; D000368:Aged; D002763:Cholecystectomy / Q000379:methods; D042883:Choledocholithiasis / Q000175:diagnosis / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D005769:Gastrointestinal Motility / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008365:Manometry; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage*; D011184:Postoperative Period; D011446:Prospective Studies; D018570:Risk Assessment; D012720:Severity of Illness Index; D013004:Somatostatin / Q000008:administration & dosage* / Q000037:antagonists & inhibitors*; D009803:Sphincter of Oddi / Q000187:drug effects*; D016896:Treatment Outcome
D013004:Somatostatin; D015282:Octreotide